CN109893500A - A kind of compound multicomponent injection - Google Patents

Abstract

The invention belongs to pharmaceutical technology fields, and in particular to a kind of compound multicomponent injection and its preparation process and purposes.Injection of the present invention is used for pyemic treatment, will not cause the generation of the adverse reactions such as allergy, and have good stability.

Description

A kind of compound multicomponent injection

Technical field

The invention belongs to pharmaceutical technology fields, and in particular to a kind of compound multicomponent injection and its preparation process and use On the way.

Background technique

Pyemia (Sepsis) is to be directed to mortality organ dysfunction caused by the host response infected is lacked of proper care, in institute Case fatality rate is up to 10% or more, causes grave danger to human health, become medical field focus of attention [referring to JAMA.2016Feb 23；315(8):801-10].Through big data retrospective analysis, in conjunction with microarray technology and leucocyte gene Expression analysis, people gradually recognize that pyemia is not only the process of a systemic inflammatory response or immune disorder, and are one The complicated chronic critical disease that a persistent inflammation, immunosupress, catabolism combine.[referring to J Trauma Acute Care Surg.2012June；72(6):1491-501,BMJ.2016May 23；353:i1585 and Medicine (Baltimore).2015Dec；94(50):e2044.].

For many years, antibiotic, antiviral drugs, blood vessel boosting drug etc. are used to pyemia traditional treatment, but not yet There are enough specific drugs for pathogenesis of sepsis mechanism to put into clinical practice.[referring to Crit Care Med.2013Feb；41 (2): 580-637] how systemic inflammatory reaction during timely correction pyemia occurrence and development, solidifying Blood dysfunction and immunologic function disorder restore proinflammatory-anti-inflammatory dynamic equilibrium of body as early as possible, are effectively improved patient's prognosis, become Important topic urgently to be resolved in treatment of sepsis medicament research and development.

The seventies, Chinese Famous emergency medicine expert professor Wang Jinda just propose treatment acute critical illness therapeutic principle of traditional Chinese medicine: Method of dissipating heat and detoxifying treats scorchingly hot card, stasis syndrome of blood stasis, and method of strengthening the body resistance to consolidate the constitution treats the acute chronic diseases marked by deficiency of vital energy, i.e. " three cards three Method ", and in this, as treating pyemic substantially big method, for clinical practice [referring to Chinese critical illness emergency medicine, 2006, 18 (11): 643-4].1975, he confirmed that endotoxemia is the infectious how dirty initiating cause of disease to decline for the first time, proposed " bacterium And control " treatment New mea-sures, with think endotoxin for body harm be inflammatory mediator in inductor generation, to play Toxic effect, it is further proposed that bacterium, endotoxin, inflammatory mediator and controlling, i.e., " bacterium is scorching simultaneously to be controlled " is [referring to the Chinese combination of Chinese tradiational and Western medicine Surgical magazine, 2012,18 (6): 553-554].

'Xuebijing ' injection is the dialectical principle according to " three three methods of card ", under the theoretical direction of " bacterium is scorching and controls ", with Based on Qing Dynasty's Wang Qingren errors in Medicine Corrected contained " xuefu zhuyu decoction ", a kind of intravenous fluid developed, by safflower, red The modern crafts such as Chinese herbaceous peony, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis gomi herbs are extracted, refine, is dry, deploying are prepared, and belong to dissolving blood stasis and detoxication Class Chinese medicine, for warming the mutual combined symptoms of the ecchymosis such as class disease, symptoms include fever, syndrome characterized by dyspnea, palpitaition, agitation；Suitable for because of infection-induced Systemic inflammatory response syndrome；Can also partner treatment multiple organ disorder syndrome organ function be damaged the phase.Xue bijing note Liquid is penetrated with antagonistic bacterium endotoxin [referring to Chinese critical illness emergency medicine, 2006,18 (11): 643-4], inhibition inflammatory factor Excessively release is [referring to Chinese critical illness emergency medicine, 2006,18 (11): 643-4, Evid Based Complement Alternat Med.2015；2015:860259 and Chin J Integr Med.2009；15 (1): 13-5], overcome blood coagulation function Energy obstacle [referring to Chinese experimental surgery magazine, 2010,27 (1): 32-4 and Chinese combination of Chinese tradiational and Western medicine first aid magazine, 2009,16 (4): 218-22 vascular endothelial cell [referring to Chinese combination of Chinese tradiational and Western medicine first aid magazine, 2009,16 (4): 218-22]], are protected, are changed It is apt to tissue microcirculation [referring to J Surg Res.2016May 1；202 (1): 147-54], improve immunologic function disorder [in Magnificent surgical magazine, 2009,47 (1): 58-61 and Evid Based Complement Alternat Med.2015；2015: The pharmacological actions such as 352642], fully demonstrated Chinese medicine multicomponent, too many levels, by all kinds of means, the effect of the Integrate adjustment of multiple target point.Greatly Sample size multiple center clinical study and meta-analysis (Meta) analysis the result shows that, be used in combination on the basis of conventional complex treatment 'Xuebijing ' injection can reduce sepsis patient 28d case fatality rate, complication rate, shorten average stay, be effectively improved Entire patient's inflammatory reaction, coagulation function and Acute physiology and chronic health evaluationⅡ score (APACHE II) scoring etc. Clinical indices, armour function significantly improve clinical efficacy [referring to Chinese critical illness emergency medicine, 2015,27 (6): 465- 76, Chinese Journal of Emergency Medicine, 2013,22 (2): 130-5 and liberation medical officer learn magazine, 2010,35 (1): 9-12].

But it is the same with most of traditional Chinese medicine injections, inevitably there is side effect [referring to yellow grain husk in 'Xuebijing ' injection Nanmu, the document analysis of 40 Xue bijing adverse reactions, township enterprise, Chinatown industry hygienic the 4th phase of August in 2012].'Xuebijing ' injection There are delayed, anaphylactic type and conventional allergic reaction, anaphylactic shock；Nausea, diarrhea, the digestive systems such as stool blood are bad Reaction；And other infusion reactions, including dizziness, nausea, phlebitis etc..It is especially the most normal with various types of allergic reactions See.Following table gives the various adverse reactions summarized in document:

It is analyzed as allergen in injection (such as chlorogenic acid etc.), cell toxicant ingredient (such as scutellarin, quercitrin Element) in action.

Inventor realizes the full composition detection of the injection, passes through blood by advanced research ideas and advanced instrument equipment Must net injection material base research, we have obtained a kind of completely new compound multicomponent injection, have remained former Xue bijing Effective component in injection eliminates the ingredient for causing toxic side effect.

Summary of the invention

The present invention provides a kind of compound multicomponent injection, which is characterized in that by danshensu, Paeoniflorin, ligustrazine, hydroxyl Carthamus tinctorius yellow colour A and pharmaceutically acceptable auxiliary material composition.

The physicochemical property of each ingredient and pharmacological action are summarized as follows:

Danshensu is one of the main pharmacodynamics ingredient in red sage root water soluble ingredient, is a kind of phenol isolated from Radix Salviae Miltiorrhizae for 1980 Property aromatic acid compound, also known as saivianic acid A, entitled D (+)-β-(the 3,4 1 the second light industry bureau base phenyl) lactic acid of chemistry [D (+) β-(3, 4-Dihydroxyphenyl)lactic acid].It is the long acicular crystal of white, molecular formula C₉H₁₀O₅.Chemical structure is such as Under:

Danshensu has the function of diminution myocardial infarct size and the mitigation course of disease, while to Myocardial Ischemia Reperfusion Injury With protective effect.The aggregation of blood platelet can obviously be inhibited, and obviously increase the mobility of platelet membrane, prompt it to coronary heart disease Effectively.The fibrinolytic of body can be improved in danshensu, improves hemorheological property, improves the deformability of red blood cell and reconciles blood Viscosity, improve the microcirculation barrier of each internal organs of whole body (especially drug arrive first at heart, liver, lungs and pancreas) Hinder, facilitates the correction of the severe complications such as rehabilitation and the adult respiratory distress syndrome (ARDS) of body tissue.Flow of calcium ions is prevented, It significantly inhibits rat peritoneal macrophages and generates prostaglandin E2 (DGE2) and thrombus ball B2 (TXB2).Danshensu can significantly inhibit By a large amount of secretions (P < 0.05) of the above-mentioned factor of endotaxin induction, there is anti-inflammatory and enhancing immunity of organism effect.Danshensu energy The obvious rat platelet aggregation in vitro for inhibiting to be induced by ADP is active, after extension electro photoluminescence rat carotid artery when thrombosis Between, hence it is evident that the whole blood viscosity of the reduction basic, normal, high shear rate of rat's blood stasis model, blood viscosity, hematocrit, Casson yield stress, Erythrocyte electrophoretic time and erythrocyte aggregation index.Danshensu has inhibiting effect to cytokine activation endothelial cell, thus Be conducive to protect vascular endothelial cell, reduce leukocyte.

Paeoniflorin, molecular formula C₂₃H₂₈O₁₁, CAS 23180-57-6 is that (90% is the amorphous chocolate brown powder of hygroscopicity Off-white powder), fusing point: 96 DEG C.Paeoniflorin stablizes (pH2~6) under acidic environment, unstable under alkaline environment.Structure It is as follows:

Paeoniflorin energy coronary artery dilator increases coronary flow, fights acute myocardial ischemia, reduces blood pressure.Paeoniflorin pair ADP and collagen-induced Platelet have different degrees of inhibiting effect.

Paeoniflorin has reduction effect to normal mouse body temperature, has conductive force to the mouse of artificial fever.Carrageenan There is inhibiting effect with rat swell-foot caused by dextran, has preventive and therapeutic effect to rat assist agent arthritis.

Ligustrazine, colorless needle crystals, 80-82 ° of fusing point (micro- measurement), 190 ° of boiling point.With special foreign odor, there is moisture absorption Property, Yi Shenghua.It is soluble in hot water, petroleum ether, chloroform, dilute hydrochloric acid is dissolved in, is slightly soluble in ether, cold water is not dissolved in, commonly uses its phosphoric acid Salt or hydrochloride, structure are as follows.

Ligustrazine can dose dependent increase coronary flow, expansion and reduces blood pressure at peripheral blood vessel, and protection blood vessel endothelium is thin Born of the same parents mitigate capillary permeability.Ligustrazine has strong inhibition to Platelet Aggregation in Rabbits caused by ADP, collagen, thrombin induction Effect inhibits the generation of blood platelet malonaldehyde, but the platelet aggregation unrestraint effect of exogenous arachidonic acid-induction.River Rhizome of chuanxiong piperazine reduces whole blood viscosity, and red blood cell and platelet electrophoresis are accelerated, and reduces fibrinogen, inhibition thrombosis.Ligustrazine can Improve experimental microcirculation and blood stasis obstacle, increase diameter of capillary, change blood flow fluidised form, blood flow velocity is speeded, blood flow Increase, open capillary vessel number increases, and can inhibit leukoplania.

Hydroxyl radical carthamin yellow carthamus A, molecular formula: C27H32O16, molecular weight: 612.53, No. Cas: 78281-02-4.

Hydroxyl radical carthamin yellow carthamus A (hydroxysafflor yellow A) is the chemical combination with single chalcone glycoside structure Object is the most effective water soluble part of safflower pharmacological effect, can inhibit platelet activating factor induction platelet aggregation with release It puts, inhibits to contestable the combination of platelet activating factor and platelet receptor, be that the activating microcirculation and removing stasis medicinal of carthamin yellow is effective Ingredient.Chemical structure is as follows:

Further, the compound multicomponent injection, composition are as follows:

The solubilizer is polyoxyethylene sorbitan monoleate；The antioxidant is ascorbic acid；The stabilizer is glycerol.

Preparation process:

Step 1: taking 80% water for injection of recipe quantity, sequentially add solubilizer, antioxidant stirs, dissolution；

Step 2: successively take recipe quantity danshensu, ligustrazine, Paeoniflorin, hydroxyl radical carthamin yellow carthamus A sets in step 1 acquired solution, Stirring, dissolution；

Step 3；Recipe quantity stabilizer is taken, is added in step 2 acquired solution, is stirred, dissolution；

Step 4；It adds to the full amount of water for injection, is 5.5- with 0.1M hydrochloric acid or 3 acquired solution pH value of sodium hydroxide regulating step 6.0；Step 5: taking step 4 gained medical fluid, 0.1% active carbon is added, stand 30min, adsorb endotoxin, pass sequentially through 0.22um Miillpore filter twice, removes active carbon；

Step 6；Step 5 gained medical fluid is taken, into 20mL in borosilicate glass ampoule, sealing is injection subject to sterilization for packing；Step 7: taking injection subject to sterilization obtained by step 6,121 DEG C, moist heat sterilization 15min is cooled to room temperature, obtains finished product.

Further, the compound multicomponent injection, composition are as follows:

Another composition of the compound multicomponent injection is as follows:

Another composition of the compound multicomponent injection is as follows:

Further, freeze-drying branch can also be added on the basis of stabilizer is not added in the compound multicomponent injection Agent, mannitol are held, one of dextran is further prepared into lyophilized preparation.Prescription and preparation process are as described below:

Step 1: taking 80% water for injection of recipe quantity, sequentially add polyoxyethylene sorbitan monoleate, ascorbic acid stirs, dissolution；

Step 2: successively take recipe quantity danshensu, ligustrazine, Paeoniflorin, hydroxyl radical carthamin yellow carthamus A sets in step 1 acquired solution, Stirring, dissolution；

Step 3；Recipe quantity frozen-dried supporting agent is taken, is added in step 2 acquired solution, is stirred, dissolution；

Step 4；It adds to the full amount of water for injection, is 5.5- with 0.1M hydrochloric acid or 3 acquired solution pH value of sodium hydroxide regulating step 6.0；

Step 5: taking step 4 gained medical fluid, 0.1% active carbon is added, stand 30min, adsorb endotoxin, pass sequentially through 0.22um Miillpore filter twice, removes active carbon；

Step 6；Step 5 gained medical fluid is taken, packing in Pyrex control bottle, is partly jumped a queue into 20mL, for injection to be lyophilized； Step 7: taking injection to be lyophilized obtained by step 5, freeze-drying, Quan Jiasai obtains finished product.

Any compound multicomponent injection of the present invention, it is characterised in that administration mode is drug administration by injection.

Any compound multicomponent injection of the present invention is used to prepare the purposes for the treatment of medication for treating pyemia.

The technical solution of the invention patent is further illustrated through the following experiment:

There is treatment to pyemia cell model and septicopyemia disease mouse model and make in compound multicomponent injection of the invention With prompt, compound multicomponent injection of the present invention has therapeutic effect for the pyemia of mammal, and then to people The pyemia of body has therapeutic effect, while not having the side effects such as sensitization.

Beneficial effects of the present invention are further illustrated below by way of experimental data:

Test the influence of compound multicomponent injection induced by endotoxin induction pyemia dead mouse

Experimental animal: Balb/C male mice (is purchased from China Concord Medical Science University's Experimental Animal Center), cleaning grade, 6-8 week old, Weight 19-23g, adaptive feeding 3 days.

Drug and reagent: drug of the present invention is prepared according to embodiment 1-2；Endotoxin is purchased from Sigma Co., USA.

Experimental method

1.1 groupings and intervention

180 mouse are randomly divided into normal group, model group, Xue bijing group, experimental group 1- experimental group 6, and every group each 20.Before experiment 12h fasting is weighed and is grouped according to random digits table.Model group only carries out endotoxin and attacks malicious modeling；Experimental group 1- is real Group 6 and Xue bijing group are tested after endotoxin attacks malicious modeling, receives embodiment 1-2, six prescription compound multicomponent injections respectively (successively giving experimental group 1- experimental group 6 from 2 prescription 1 of embodiment to 2 prescription 6 of embodiment) and 'Xuebijing ' injection drug administration by injection are dry In advance；Normal group does not do additional intervention.

It is as follows that endotoxin attacks malicious modeling process: anaesthetic selects ketalar: Su Mian Xin II:PBS (phosphate-buffered Liquid)=1:1.5:2.5 mixed liquor, with 2mL/kg dosage intramuscular anesthesia.After anesthesia is satisfied, fixed mouse is in operating table, abdomen Intracavitary administration endotoxin 10mg/kg.Experimental group 1- experimental group 6 and Xue bijing group 30min, 60min and interior before endotoxin attacks poison Respectively auricular vein injects embodiment 1-2, six prescription compound multicomponent injections and Xue bijing to 30min respectively after toxin attacks Injection, dosage are 4mL/kg weight；Respectively ear edge is quiet by 30min after 30min, 60min before this and endotoxin challenge for model group Arteries and veins injecting normal saline 4mL/kg weight again.

1.2 observations and mortality statistics

Dead mouse is counted per observation for 24 hours, Kaplan-Meier method statisticallys analyze (statistical software uses SPSS16.0), p < 0.05 is there are significant differences.

Experimental result

The result shows that the death rate of sepsis model group is 100%, and experimental group 1- experimental group 6 after endotoxin injection in 7 days And the death rate of Xue bijing group is as shown in the table, seven groups of the death rate is significantly lower than sepsis model group (p < 0.05), and With control group without significant difference.

Above-mentioned discovery prompt, prompts embodiment 1-2, pyemia caused by six prescription compound multicomponent injection induced by endotoxin Mouse has protective effect, and protective effect is suitable with 'Xuebijing ' injection.

1 embodiment 1-2 of table, pyemia caused by six prescription compound multicomponent injections and 'Xuebijing ' injection induced by endotoxin The influence of dead mouse

Note: * indicates p < 0.05 compared with model group.

Test the influence for the pyemia dead mouse that two compound multicomponent injections mediate cecal ligation and perforation art

Experimental animal

Balb/C male mice (is purchased from China Concord Medical Science University's Experimental Animal Center), cleaning grade, 6-8 week old, weight 19- 23g, adaptive feeding 3 days.

Drug and reagent

Drug of the present invention is prepared according to embodiment 1-2；'Xuebijing ' injection (Tianjin red sun medicine company).

Experimental method

2.1 groupings and intervention

180 mouse are randomly divided into control group, model group, Xue bijing group, experimental group 1- experimental group 6, and every group each 20.Before experiment 12h fasting is weighed and is grouped according to random digits table.Control group only carries out same surgical procedure, but caecum is neither Ligation does not also puncture；Model group carries out cecal ligation and perforation art (CLP) modeling；Experimental group 1- experimental group 6 is divided after CLP modeling Not Zhu She embodiment 1-2, six prescription compound multicomponent injections (successively give from 1 prescription 1 of embodiment to 2 prescription 6 of embodiment Experimental group 1- experimental group 6) pharmaceutical intervention is given, Xue bijing group injection 'Xuebijing ' injection gives pharmaceutical intervention.

CLP modeling process is as follows: anaesthetic selects ketalar: Su Mian Xin II:PBS=1:1.5:2.5 mixed liquor, With 2mL/kg dosage intramuscular anesthesia.After anesthesia is satisfied, fixed mouse is in operating table, thorax abdomen routine disinfection drape, xiphoid-process Median abdominal incision, incision length 1.5cm are at lower l cm.Exposure caecum, ligatures, and avoid blood vessel with 21G syringe needle and pass through at 1/2 The caecum for wearing ligation is primary.After confirming non-activity bleeding, caecum is also received into abdominal cavity, suturing them notch.Skin is normal after postoperative neck Physiological saline lmL liquid resuscitation is subcutaneously injected in rule disinfection, and single cage is raised after recovery from anesthesia.After mouse row CLP operation, experimental group 1- experimental group 6 and Xue bijing group, 0.5h, 12h after surgery, for 24 hours, 36h, 48h, 60h, 72h, 84h, 96h distinguish from auricular vein Inject embodiment 1-2, six prescription compound multicomponent injections and 'Xuebijing ' injection, dosage 4mL/kg；Model group and right According to group in the corresponding time from auricular vein injecting normal saline 4mL/kg weight.

2.2 observations and mortality statistics

Each group death mouse is counted per observation for 24 hours, Kaplan-Meier method statisticallys analyze (statistical software uses SPSS16.0), P < 0.05 is that there are significant differences.

Experimental result

The result shows that the death rate of sepsis model group is 70%, and experimental group 1- experimental group 6 and blood after CLP operation in 7 days The death rate that must be organized only is as shown in the table.Its death rate is significantly lower than sepsis model group (p < 0.05), prompts embodiment 1-2 Pyemia mouse caused by six prescription compound multicomponent injections and the equal induced by endotoxin of 'Xuebijing ' injection has protective effect, and And six prescription compound multicomponent injections of embodiment 1-2 are suitable with the protective effect of 'Xuebijing ' injection.

2 embodiment 1-2 of table, the pyemia that six prescription compound multicomponent injections and 'Xuebijing ' injection mediate CLP The influence of dead mouse

Note: * indicates P < 0.05 compared with sepsis model group.

Test influence of the three compound multicomponent injections to high mobility group box 1 protein in rats with sepsis

Experimental animal

Wistar male rat (is purchased from Institute of Experimental Animals, Chinese Academy of Medical Sciences), cleaning grade, and weight 180-220g is adapted to Property raising 1 week.

Drug and reagent

Drug of the present invention is prepared according to embodiment 1-2；High mobility group protein B 1 (HMGB1) enzyme linked immunosorbent assay (ELISA) Kit (Japanese Shino-Test company)；'Xuebijing ' injection (Tianjin red sun medicine company).

Experimental method

3.1 groupings and intervention

90 rats are randomly divided into control group, model group, Xue bijing group, experimental group 1- experimental group 6, and every group each 10.Before experiment 12h fasting is weighed and is grouped according to random digits table.Control group only opens skin suture after abdomen exposure caecum, subcutaneous to infuse Penetrate the recovery of 10ml physiological saline；Sepsis model group carries out cecal ligation and perforation art (CLP) modeling；Experimental group 1- experimental group 6 and Xue bijing group injects embodiment 1-2, six prescription compound multicomponent injections are (from 1 prescription 1 of embodiment after CLP modeling respectively Successively give experimental group 1- experimental group 6 to 2 prescription 6 of embodiment) and 'Xuebijing ' injection give pharmaceutical intervention.

CLP modeling process is as follows: big with ketamine injection+Su Mian Xin II injection 2:1 mixed liquor intramuscular anesthesia Mouse prepares pyemia animal model using CLP.Cecal ligation and ileum junction penetrate through 2 formation intestines of caecum with No. 18 syringe needles Fistula, and 2 drainage strips (0.5cm × 2.0cm) of indwelling prevent pin hole from healing, rear layer-by-layer suture skin, art finishes to be subcutaneously injected immediately The recovery of 10mL physiological saline.After rats underwent CLP operation, experimental group 1- experimental group 6 and Xue bijing group 2h, 12h after surgery, for 24 hours, 36h, 48h and 60h inject embodiment 1-2, six prescription compound multicomponent injections and Xue bijing note through vena dorsalis penis respectively Penetrate liquid, dosage 4mL/kg；Model group and control group are in the corresponding time through vena dorsalis penis injecting normal saline 4mL/kg weight.

3.2 blood samplings and detection

2h, 8h after CLP, for 24 hours, 48h and 72h, abdominal aorta sterile blood sampling 3mL, utilizes enzyme linked immunological after groups of animals is anaesthetized Absorption method (ELISA) detects blood plasma HMGB1 content.

Experimental result

The result shows that containing a small amount of HMGB1 in control group blood plasma；CLP early postoperative period, model group HMGB1 content is i.e. obvious to be increased Add, 8hHMGB1 level further increases, and is gradually reduced in for 24 hours, but postoperative 72h is still higher than control group, difference has statistics meaning Adopted (p < 0.05).And experimental group 1- experimental group 6 and Xue bijing group are respectively through embodiment 1-2, six prescription compound multicomponent injections Liquid and 'Xuebijing ' injection inject therapeutic intervention, and plasma content is significantly lower than model group (p < 0.05) after postoperative 2h, for 24 hours after HMGB1 decline becomes apparent (p < 0.01), close to control group level.

Above-mentioned discovery prompt, prompts embodiment 1-2, six prescription compound multicomponent injections and 'Xuebijing ' injection are to purulence The expression of HMGB1 is inhibited when toxication, and embodiment 1-2, such suppression of six prescription compound multicomponent injections Production is suitable for 'Xuebijing ' injection.

3 embodiment 1-2 of table, six prescription compound multicomponent injections and 'Xuebijing ' injection are to rats with sepsis blood plasma HMGB1 level influence (N=10) unit: μ g/L

Group	Postoperative 2h	Postoperative 8h	It is postoperative for 24 hours	Postoperative 48h	Postoperative 72h
						Control group	8.5±2.5	8.2±1.5	8.0±2.5	8.3±2.6	8.3±1.2
Model group	27.6±9.2#	30.6±5.2#	24.2±5.3#	14.1±2.3#	16.3±1.5#
						Xue bijing group	15.8±5.7*	18.9±6.3*	8.3±2.3*	7.8±2.0*	8.5±2.3*
Experimental group 1	17.0±5.4*	19.1±6.8*	8.9±2.7*	6.9±1.6*	8.9±1.4*
						Experimental group 2	16.5±5.6*	17.6±4.7*	9.0±1.8*	7.8±1.5*	7.7±1.5*
Experimental group 3	16.9±5.6*	17.6±4.0*	8.5±2.3*	7.5±1.9*	8.3±2.4*
						Experimental group 4	17.2±5.4*	18.0±5.9*	8.2±2.5*	7.2±1.9*	7.8±2.0*
Experimental group 5	15.7±5.3*	19.2±5.7*	8.7±2.1*	7.6±1.9*	7.4±2.2*
						Experimental group 6	16.2±5.3*	17.7±6.4*	8.6±2.4*	7.9±1.9*	7.4±2.3*

Note: # indicates p < 0.05 compared with the control group；* p < 0.05 compared with model group is indicated.

Four compound multicomponent injections are tested to rats with sepsis monocyte protein enzyme activition receptor -1 and tissue factor expression Influence experimental animal

Wistar male rat (is purchased from Institute of Experimental Animals, Chinese Academy of Medical Sciences), cleaning grade, and weight 180-220g is adapted to Property raising 1 week.

Drug and reagent

Drug of the present invention is prepared according to embodiment 1-2；Tissue factor (TF) enzyme linked immunosorbent assay (ELISA) kit (U.S. USCN company)；Fluorescein isothiocynate (FITC) marks anti-rat monocyte protein enzyme activition receptor -1 (PAR-1) antibody (Santa Cruz company, the U.S.)；'Xuebijing ' injection (Tianjin red sun medicine company).

Experimental method

4.1 groupings and intervention

90 rats are randomly divided into control group, model group, Xue bijing group, experimental group 1- experimental group 6, and every group each 10.Before experiment 12h fasting is weighed and is grouped according to random digits table.Control group only opens skin suture after abdomen exposure caecum, subcutaneous to infuse Penetrate the recovery of 10mL physiological saline；Sepsis model group carries out cecal ligation and perforation art (CLP) modeling；Experimental group 1- experimental group 6 and Xue bijing group injects embodiment 1-2, six prescription compound multicomponent injections are (from 1 prescription 1 of embodiment after CLP modeling respectively Successively give experimental group 1- experimental group 6 to 2 prescription 6 of embodiment) and 'Xuebijing ' injection give pharmaceutical intervention.

CLP modeling process is as follows: big with ketamine injection+Su Mian Xin II injection 2:1 mixed liquor intramuscular anesthesia Mouse prepares pyemia animal model using CLP.Cecal ligation and ileum junction penetrate through 2 formation intestines of caecum with No. 18 syringe needles Fistula, and 2 drainage strips (0.5cm × 2.0cm) of indwelling prevent pin hole from healing, rear layer-by-layer suture skin, art finishes to be subcutaneously injected immediately The recovery of 10mL physiological saline.After rats underwent CLP operation, experimental group 1- experimental group 6 and Xue bijing group 2h, 12h after surgery, for 24 hours, 36h, 48h and 60h are injected through vena dorsalis penis and are injected embodiment 1-2 respectively, and six prescription compound multicomponent injections and blood must Net injection, dosage 4mL/kg；Model group and control group are in the corresponding time through vena dorsalis penis injecting normal saline 4mL/kg Weight.

4.2 blood samplings and detection

12h after CLP, for 24 hours, 48h and 72h, abdominal aorta sterile blood sampling 3mL after groups of animals is anaesthetized.It is immunized using streaming glimmering Light method, detection blood plasma monocyte protein enzyme activition receptor -1 (PAR-1) expression；Utilize enzyme linked immunosorbent assay (ELISA), inspection Survey plasma tissue factor (TF) content.

PAR-1 detection of expression: taking 2mL heparin anti-coagulating, separates mononuclearcell using rat lymphocyte separating liquid.With Mononuclearcell is resuspended in the complete cell culture fluid of 10% fetal calf serum-RPMI 1640, and adjustment cell density is 4 × 106/mL, incubates It educates and rinses tissue culture plate with cell culture fluid after 2h.0.25% trypsase-EDTA digestive juice is added to digest 3min, to major part After cell detachment, add the complete cell culture fluid 2mL of 10% fetal calf serum-RPMI 1640, terminates digestion.Phosphate buffer (PBS) it rinses 3 times, to obtain peripheral blood mononuclear cells.The 1 cell isosulfocyanic acid fluorescence of μ g/1 × 106 is added in cell suspension Plain (FITC) marks anti-P of Rats AR-1 antibody, and 4 DEG C are protected from light incubation 15min, and 2mL PBS is added and washs 1 time, 0.4mL is added PBS, flow cytometer detect its average fluorescent strength.

Experimental result

The result shows that there is certain expression in control group monocyte PAR-1；Model group after surgery 12h PAR-1 expression quantity with it is right It is not statistically significant according to group comparing difference, for 24 hours after surgery, 48h and 72h its average fluorescent strength be then significantly higher than control group (p < 0.05) it, and with the extension of Post surgery duration gradually increases.The PAR-1 of seven intervention groups of experimental group 1- experimental group 6 and Xue bijing group Average fluorescent strength is for 24 hours, 48h and 72h occur significantly reducing (p < 0.05) compared with model group.

And there is certain expression in control group monocyte TF；Model group 12h after surgery, for 24 hours, 48h and 72h TF expression are equal It is significantly higher than control group (p < 0.05), and is gradually increased with the extension of Post surgery duration, is culminated in 48h.Experimental group 1- is real The TF for testing group 6 and seven intervention groups of Xue bijing group is expressed for 24 hours, 48h and 72h occur with model group compared with significant decrease (p < 0.05)。

Above-mentioned discovery prompt, embodiment 1-2, six prescription compound multicomponent injections can lower the monokaryon of pyemia induction The expression of cell PAR-1, hence it is evident that reduce the secretion of TF, improve the Coagulation Dysfunction that monocyte mediates, and this effect with 'Xuebijing ' injection is suitable.

Influence that table 4-1 compound multicomponent injection and 'Xuebijing ' injection express rats with sepsis PAR-1 ( N=10)

Group	Postoperative 12h	It is postoperative for 24 hours	Postoperative 48h	Postoperative 72h
					Control group	20.0±0.7	17.6±2.0	15.7±0.2	16.8±2.9
Model group	19.5±1.0	21.2±1.0#	25.1±0.6#	28.3±0.5#
					Xue bijing group	19.7±2.0*	18.7±1.8*	20.2±1.9*	19.2±1.8*
Experimental group 1	20.2±2.1*	19.4±1.9*	19.6±2.0*	19.2±1.8*
					Experimental group 2	20.2±2.3*	19.0±1.9*	19.5±2.1*	19.3±1.9*
Experimental group 3	19.7±2.0*	18.9±1.9*	19.8±1.9*	20.2±1.7*
					Experimental group 4	20.2±2.0*	19.2±1.8*	19.1±2.0*	18.9±1.9*
Experimental group 5	19.9±2.3*	18.9±2.0*	20.2±1.8*	18.8±2.0*
					Experimental group 6	19.7±2.0*	20.2±1.9*	20.2±1.9*	20.6±1.7*

Note: # indicates p < 0.05 compared with the control group；* p < 0.05 compared with model group is indicated.

Influence that table 4-2 compound multicomponent injection and 'Xuebijing ' injection express rats with sepsis blood plasma TF (N=10) unit: ng/L

Group	Postoperative 12h	It is postoperative for 24 hours	Postoperative 48h	Postoperative 72h
					Control group	237.2±15.5	220.2±40.5	255.1±27.5	242.3±34.5
Model group	325.1±17.9#	506.1±85.3#	698.1±132.1#	345.1±35.2#
					Xue bijing group	266.6±28.6*	276.3±23.7*	259.7±22.3*	271.6±21.7*
Experimental group 1	261.7±35.4*	280.1±38.7*	267.3±29.9*	269.7±22.5*
					Experimental group 2	265.0±32.8*	266.8±27.3*	255.5±37.2*	280.9±32.7*
Experimental group 3	265.4±32.4*	279.6±22.2*	278.2±25.9*	267.5±35.7*
					Experimental group 4	259.1±21.8*	276.7±27.2*	274.0±32.6*	266.7±25.6*
Experimental group 5	259.7±31.6*	278.1±21.8*	269.1±30.5*	282.7±31.7*
					Experimental group 6	272.7±22.1*	275.1±34.9*	276.2±20.4*	265.7±30.9*

Note: # indicates p < 0.05 compared with the control group；* p < 0.05 compared with model group is indicated.

Shadow of the experiment five compound multicomponent injection to rats with sepsis regulatory T-cell apoptosis and helper T lymphocyte drift Ring experimental animal

Wistar male rat (is purchased from Institute of Experimental Animals, Chinese Academy of Medical Sciences), cleaning grade, and weight 180-220g is adapted to Property raising 1 week.

Drug and reagent

Drug of the present invention is prepared according to embodiment 1-2；Phycoerythrin (PE)-anti-rat CD25, fluorescein isothiocynate (FITC) Mark anti-rat CD4, allophycocyanin (APC) label annexin V (Annexin V) apoptosis kit (U.S. company BD)； The anti-PE kit of rat, CD4 magnetic bead, MiniMACS Magnetic Isolation instrument and sorting column (German MiltenyiBiotec company)； PE mark plug winged-helix transcription factor (Foxp3) kit, PE Labeled T-Lymphocytes toxicity antigen 4 (CTLA-4), Anti- rat CD3 monoclonal antibody, anti-rat CD28 monoclonal antibody (eBioscience company, the U.S.)；Interferon (IFN) -7, IL-4, IL-10 enzyme linked immunosorbent assay (ELISA) kit (Biosource company, the U.S.)；IL-17ELISA kit (beauty Usenlife Science company, state)；Trypan blue (Sigma Co., USA)；'Xuebijing ' injection (Tianjin red sun medicine company).

Experimental method

5.1 groupings and intervention

90 rats are randomly divided into control group, model group, Xue bijing group, experimental group 1- experimental group 6, and every group each 10.Before experiment 12h fasting is weighed and is grouped according to random digits table.Control group only opens skin suture after abdomen exposure caecum, subcutaneous to infuse Penetrate the recovery of 10mL physiological saline；Sepsis model group carries out cecal ligation and perforation art (CLP) modeling；Experimental group 1- experimental group 6 and Xue bijing group injects embodiment 1-2, six prescription compound multicomponent injections are (from 2 prescription 1 of embodiment after CLP modeling respectively Successively give experimental group 1- experimental group 6 to 2 prescription 6 of embodiment) and 'Xuebijing ' injection give pharmaceutical intervention.

CLP modeling process is as follows: big with ketamine injection+Su Mian Xin II injection 2:1 mixed liquor intramuscular anesthesia Mouse prepares pyemia animal model using CLP.Cecal ligation and ileum junction penetrate through 2 formation intestines of caecum with No. 18 syringe needles Fistula, and 2 drainage strips (0.5cm × 2.0cm) of indwelling prevent pin hole from healing, rear layer-by-layer suture skin, art finishes to be subcutaneously injected immediately The recovery of 10mL physiological saline.

After rats underwent CLP operation, experimental group 1- experimental group 6 and Xue bijing group are infused through vena dorsalis penis injection respectively after surgery It penetrates

Embodiment 1-2, six prescription compound multicomponent injections and 'Xuebijing ' injection, dosage 4mL/kg；Model group and right According to group in the corresponding time through vena dorsalis penis injecting normal saline 4mL/kg weight.

5.2 isolation and culture of cell

Each group rat is sterile after disconnected neck is put to death respectively to take spleen, and 400 mesh filter screens are crossed after grinding, leaching is added after cell suspension centrifugation Bar cell separating liquid centrifuging and taking middle layer white cell.The anti-CD25 and PE magnetic bead of PE- is added, positive selection (sun choosing) obtains CD25+T Cell, Solid phase (yin choosing) obtain CD25-T cell.After the dissociation of CD25+T cell dissociation reagent, yin selects cell with FITC- Anti- CD4 and CD4 magnetic bead sun selects up to CD4+CD25+Treg；CD25-T cell is selected with the anti-CD4 and CD4 magnetic bead sun of FITC- to obtain the final product CD4+CD25-T cell.The purity of flow cytomery double positive cells.With 0.4% trypan blue of mass fraction to CD4+CD25 + Treg is dyed, and cell survival rate is observed.It is trained with the RPMll640 culture solution of 20% calf serum containing volume fraction in 48 holes It supports in plate, is cultivated in CO2 incubator.Each group cultivates 12h in separation CD4+CD25+Treg on the 3rd, then is adjusted with culture solution CD4+CD25+Treg and CD4+CD25-T cell concentration is 1:1 culture, and concanavalin A (Con A, 5mg/L) is stimulated, 37 DEG C Centrifuging and taking supernatant after culture 68h, to be checked in -70 DEG C of frosts in CO2 incubator.

5.3 detections and analysis

The detection of Treg apoptosis rate: 12h is cultivated after separation cell, suspension CD4+CD25+Treg (1 × 109/L) uses phosphate-buffered Liquid (PBS) is washed 2 times, and the 10 μ L of Annexin V (20mg/L) of 100 μ L combination buffers and APC label is added, and room temperature is protected from light 30min adds 10 μ L of actinomycin D (7-AAD), and after being protected from light 5min, 400 μ L combination buffers, fluidic cell is added It is apoptotic cell that instrument, which selects 7-AAD feminine gender Annexin V positive cell, detects apoptosis rate.

Foxp3 and CTLA-4 detection of expression: the CD4 that 100 μ L are prepared.CD25+Treg(1×10⁹/ L) add 1m1 newly to prepare Rupture of membranes liquid, 4 DEG C are protected from light and are incubated for 2h, then are washed with 2mL rupture of membranes buffer；Add the anti-Foxp3 of PE-, after the incubation 30min of 4 DEG C of dark place It is washed with 2mL rupture of membranes buffer, supernatant is abandoned in centrifugation, and 0.5mL PBS, the mean fluorecence of flow cytomery Foxp3 is added Intensity.Cell (1 × 10 is resuspended⁹/ L) in directly plus PE-CTLA-4,4 DEG C are protected from light and are incubated for 30min, detect CTLA-4 mean fluorecence Intensity.

Cytokines measurement: the IFN-γ of major inhibitory cell factor IL-10, the Thl secretion including Treg secretion, The IL-4 of Th2 secretion.IL-10 Specimen origin cultivates the supernatant collected after 12h, IFN-γ, IL-4 in the Treg that each group separates Supernatant of the Specimen origin after CD4+CD25+Treg and CD4+CD25-T cell co-cultures 68h.It is detected with ELISA kit, Stringent by specification operation, calculates separately out standard curve and regression equation, sample absorbance is substituted into standard curve, is calculated The protein concentration of the cells in sample factor.

Experimental result

The result shows that: model group Treg apoptosis rate is significantly lower than control group (p < 0.05), and experimental group 1- experimental group 6 is all remarkably higher than Model group (p < 0.05), model group Foxp3, CTLA-4 expression be apparently higher than control group (p < 0.05), experimental group 1- experimental group 6 and Xue bijing group is substantially less than model group (p < 0.05), and model group IL-10 secretion level is apparently higher than control group (p < 0.05), and Experimental group 1- experimental group 6 and Xue bijing group are substantially less than model group (p < 0.05), and model group IFN-γ and IL-4 level are more right It is significantly increased according to group, the IFN-γ and IL-4 level of experimental group 1- experimental group 6 and Xue bijing group further increase, with model Group is statistically significant (p < 0.05) compared to difference.

Above-mentioned discovery prompt, embodiment 1-2, six batch compound multicomponent injections can promote pyemia Treg apoptosis, Improve Treg, effector T cell cytokine secretion, facilitate correct body cell immunosuppressive condition, and this effect with 'Xuebijing ' injection is suitable.

Table 5-1 embodiment 1-2, six prescription compound multicomponent injections and 'Xuebijing ' injection are to rats with sepsis Treg Apoptosis rate and Foxp3, CTLA-4 expression influence (N=10) unit: %

Group	Apoptosis rate	Foxp3	CTLA
				Control group	9.48±2.2	126.5±12.2	119.1±6.4
Model group	5.9±1.5#	175.0±19.6#	172.0±10.1#
				Xue bijing group	23.7±2.7*	59.6±3.6*	55.7±4.6*
Experimental group 1	23.2±2.8*	59.7±5.7*	55.5±6.1*
				Experimental group 2	24.0±2.8*	56.1±3.7*	56.2±4.1*
Experimental group 3	26.0±2.9*	57.2±3.7*	57.1±4.7*
				Experimental group 4	21.1±2.7*	56.1±3.4*	58.0±4.5*
Experimental group 5	26.6±2.6*	59.9±5.6*	58.5±3.9*
				Experimental group 6	20.9±2.9*	56.9±6.1*	58.5±3.2*

Note: # indicates p < 0.05 compared with the control group；* p < 0.05 compared with model group is indicated.

Table 5-2 embodiment 1-2, six prescription compound multicomponent injections and 'Xuebijing ' injection are to rats with sepsis Treg, effector T cell secrete cytokines level influence (N=10) unit: ng/L

Group	IL-10	IFN-γ	IL-4
				Control group	133.7±25.7	19.0±6.7	5.4±0.7
Model group	318.1±28.3#	254.7±44.9#	8.8±0.6#
				Xue bijing group	50.0±2.1*	496.2±81.8*	10.4±1.0*
Experimental group 1	49.3±2.3*	496.0±87.0*	10.7±0.9*
				Experimental group 2	49.9±2.4*	495.0±80.5*	10.4±1.2*
Experimental group 3	49.3±2.4*	500.3±83.1*	10.6±1.2*
				Experimental group 4	50.8±2.5*	500.7±82.6*	10.8±1.2*
Experimental group 5	50.8±2.1*	497.0±79.7*	10.8±0.9*
				Experimental group 6	49.0±2.2*	501.6±86.8*	10.6±1.3*

Note: # indicates p < 0.05 compared with the control group；* p < 0.05 compared with model group is indicated.

Six compound multicomponent injections and 'Xuebijing ' injection are tested, normal assays animal adverse reaction is observed after administration 6.1 experimental animal

BN rat, male, 6 week old are purchased from Beijing Vital River Experimental Animals Technology Co., Ltd..

6.2 reagent

Drug of the present invention is prepared according to embodiment 1-2；

Physiological saline: Shangdong Hualu Pharmaceutical Co., Ltd.:

'Xuebijing ' injection: Tianjin Chasesun Pharmaceutical Co., Ltd；

Aluminum hydroxide adjuvant, the precious biology in west

Evans blue: Sigma Co., USA；

Compound48/80: Sigma Co., USA；

The total IgE kit of rat blood serum: RapidBiolab company, the U.S.；

Rat OVA- specific IgE ELISA kit: R&Dlab company, the U.S.；

6.3 animal packets and raising

BN rat presses raising after weight is grouped at random respectively, and, in SPF grades of environment, experiment preceding quarantine is seven days, before experiment and is tested Period animal freely ingests drinking-water.

6.5 sensitization protocols and take blood

80 rats are randomly divided into control group, Xue bijing group, experimental group 1- experimental group 6, and every group each 10.Experimental group 1- experimental group 6 and Xue bijing group respectively at 1,3,5,7,9 day, respectively be subcutaneously injected embodiment 1-2, six prescription compound multicomponent injections The bodies such as (successively giving experimental group 1- experimental group 6 from 2 prescription 1 of embodiment to 2 prescription 6 of embodiment) and 'Xuebijing ' injection and mixing Product aluminum hydroxide adjuvant, dosage 4mL/kg weight, control group give physiological saline to replace.The extremely big rathole socket of the eye of 2l takes after administration Blood, after 37 DEG C of water-bath 4h, 3000rpm centrifugation 10min takes serum, and -20 DEG C save backup.

6.4 determination of total IgE levels

It is horizontal using total IgE in ELISA kit detection the 21st day serum of sensitization, using total in ELISA kit detection serum IgE concentration is operated by kit specification.Lowest detection is limited to 50ng/mL.Testing result is as follows:

Group	IgE level (ng/mL)
		Control group	1.2±0.3
Xue bijing group	1.8±0.2
		Experimental group 1	1.2±0.1
Experimental group 2	1.1±0.2
		Experimental group 3	1.2±0.1
Experimental group 4	1.1±0.1
		Experimental group 5	1.1±0.2
Experimental group 6	1.3±0.1

As shown above, total IgE concentration is suitable with control group in experimental group 1- experimental group 6BN rat blood serum, compared with the control group, Total IgE concentration has conspicuousness to increase (P < 0.05) in Xue bijing group BN rat blood serum.

The experiment of 6.5 skin pricks

Sensitization the 2l days, experimental group 1- experimental group 6 and Xue bijing group BN rat 4 and healthy rat 8 were taken respectively, are divided into Positive controls and negative control group, carry out skin prick experiment to detect the reaction of its acute skin by every group 4.Animal Anesthesia Back part shaving, rat are injected intravenously 5mg/ml Evans Blue solution 100uL respectively.Then, each group BN rat distinguishes intradermal note 6 compound multicomponent injection of 50uL experimental group 1- experimental group and 'Xuebijing ' injection are penetrated, Compound48/80 (20ug/mL) is raw Salt water is managed, after 20min is administered, animal removes skin of back after putting to death, and diameter of blue spot in vernier caliper measurement skin is greater than 5mm Person is determined as positive findings.

Skin irritation test can be used for determining the sensitization situation of mast cell in skin, with the close phase of clinical local reaction It closes, this Experimental comparison observes Mast cell activation agent 48/80 and 6 compound multicomponent injection of experimental group 1- experimental group and blood Must net injection skin irritation effect.Positive control drug 48/80 all causes strong dermoreaction in all animals, reaction Rate is 100%, and the dermoreaction that Xue bijing group can trigger 66.7% (4/6) is positive, and 6 compound multiple groups of experimental group 1- experimental group Dividing the dermoreaction positive rate of injection and control group is 0 (0/6).

6.6 general reactions observation

Sensitization the 21st day, experimental group 1- experimental group 6 and Xue bijing group BN rat 4 are taken respectively, experimental group 1- experimental group 6 is multiple respectively Square multicomponent injection and 'Xuebijing ' injection excite each group sensitization BN rat, and the systemic allergic that observation animal occurs is anti- It answers.Symptom Observation uses improved system methods of marking: 0=is asymptomatic；1=itch and scratch nose；2=hair directly erects, and activity subtracts It is few；3=asthma, is short of breath, and cyanosis occurs in oral area: 4=faints from fear；5=is dead.

Sensitization BN rat is observed using the systemic reaction after the excitation of Xue bijing group.Experimental group 1- experimental group 6BN rat swashs Without significant reaction after hair, and appearance activity reduces, is short of breath and even faints from fear after the excitation of the BN rat of Xue bijing group sensitization Phenomenon, but each group does not have animal dead.

6.7 passive cutaneous anaphylaxis tests (Passive Cutaneous Anaphylacxis, PCA)

Sensitization: taking healthy BN rat 36, is randomly divided into 9 groups, and every group 4, half male and half female.Respectively Xue bijing group (gives medicament Amount 4mL/kg weight), experimental group 1- experimental group 6 (dosage 4mL/kg weight), positive controls (give bovine serum albumin It is white, 100mg/kg weight) and negative control group (giving physiological saline, 4mL/kg weight).Sensitization 1 is injected intraperitoneally in each group next day It is secondary, totally 5 times.

Antiserum preparation: after last sensitizing injection the 10th day take a blood sample, with 2000rpm be centrifuged 10min, separate serum, -20 DEG C It saves, it is spare in two weeks.

Excitation: another 36 BN rats are randomly divided into 9 groups, and every group 4, half male and half female is grouped same sensitization test (STT).Rat two The cropping of side back portion, area about 3*4cm².Above-mentioned each group antiserum normal saline dilution is at 1:2 and 1:8.On a left side for preparatory cropping Side and right side back intradermal each corresponding group of one injection and diluted antiserum 0.1ml respectively.According to " Chinese medicine, natural after for 24 hours Drug immunotoxicity anaphylaxis, photo sensitive reaction investigative technique guideline ", each group tail vein injection is identical with priming dose Challenging antigen adds the 0.5% total 1ml of Evans blue dyestuff of equivalent, is excited.

Observation index: groups of animals is put to death in anesthesia after 30min, and clip skin of back measures the blue spot of skin inner layer Size, it is the positive that diameter, which is greater than 5mm person,.The diameter of irregular spot is the half of the sum of major diameter and minor axis.

The greatest dilution for obtaining positive findings is Specific antibody titre.

After 56 DEG C of heating 4h of antiserum again according to the above method, using PCA testing inspection, reagin type is determined.

Compared to total IgE concentration, specific IgE concentrations are directly related with anaphylactoid generation in serum, therefore use PCA Specific IgE in testing inspection serum, and IgE is removed by heating, confirm the Antibody types of generation.

Test result, display only have Xue bijing group rat, and the blue spot diameter of skin inner layer is greater than 5mm, actual measurement Four rats, 8 spot diameter mean values are 8.2mm.Xue bijing group causes PCA positive reaction, and reacting positive rate reduces after inactivation, Diameter of blue spot reduces, and causes the antibody of the PCA positive reaction to be specific IgE it is possible thereby to determine.'Xuebijing ' injection can draw It plays BN rat and generates specific IgE antibody, thus cause the allergic reaction of rat, but each prescription of experimental group 1- experimental group 6 Compound multicomponent injection does not cause the allergic reaction of rat.

Test the accelerated stability observation in 12 months of seven compound multicomponent injections

Taking six groups of samples of above-mentioned 6 prescription injections (6 prescriptions in embodiment 1-2), number A-F sets 40 DEG C ± 2 respectively respectively DEG C, it is stored 12 months under the conditions of 75% ± 5%RH, respectively at 0 month, in January, 2 months, in March, in June, correlation was measured by sampling in December Matter obtains corresponding data, as shown in the table:

6 embodiment 1-2 injection liquid samples stability of table

Table data as above can be seen that such as embodiment 1-2, the compound multicomponent of 6 prescriptions prepared by prescription 1- prescription 6 Injection stores 12 months under the conditions of 75% ± 5%RH by 40 DEG C ± 2 DEG C, and the content of each component is more than in injection 98.5%, it has good stability.

By coherent detection it was found that compound multicomponent injection of the present invention is stablized with quality, work is produced Skill is simple, easy to produce, safely and effectively, the features such as adverse reaction is few.

Specific embodiment

By following specific embodiments, the present invention is further illustrated, but without limitation.

The preparation of 1 compound multicomponent injection of embodiment

Preparation process:

Step 1: taking 80% water for injection of recipe quantity, sequentially add polyoxyethylene sorbitan monoleate, ascorbic acid stirs, dissolution；

Step 2: successively take recipe quantity danshensu, ligustrazine, Paeoniflorin, hydroxyl radical carthamin yellow carthamus A sets in step 1 acquired solution, Stirring, dissolution；

Step 3；Recipe quantity glycerol is taken, is added in step 2 acquired solution, is stirred, dissolution；

Step 4；It adds to the full amount of water for injection, is 5.5- with 0.1M hydrochloric acid or 3 acquired solution pH value of sodium hydroxide regulating step 6.0；

Step 5: taking step 4 gained medical fluid, 0.1% active carbon is added, stand 30min, adsorb endotoxin, pass sequentially through 0.22um Miillpore filter twice, removes active carbon；

Step 6；Step 5 gained medical fluid is taken, into 20mL in borosilicate glass ampoule, sealing is injection subject to sterilization for packing；

Step 7: taking injection subject to sterilization obtained by step 6,121 DEG C, moist heat sterilization 15min is cooled to room temperature, obtains finished product.

The preparation of 2 compound multicomponent injection freeze-dried powder of embodiment

Preparation method:

Step 1: taking 80% water for injection of recipe quantity, sequentially add polyoxyethylene sorbitan monoleate, ascorbic acid stirs, dissolution；

Step 2: successively take recipe quantity danshensu, ligustrazine, Paeoniflorin, hydroxyl radical carthamin yellow carthamus A sets in step 1 acquired solution, Stirring, dissolution；

Step 3；It takes recipe quantity frozen-dried supporting agent (mannitol, Dextran 40 or dextran 60), step 2 acquired solution is added In, it stirs, dissolution；

Step 4；It adds to the full amount of water for injection, is 5.5- with 0.1M hydrochloric acid or 3 acquired solution pH value of sodium hydroxide regulating step 6.0；

Step 5: taking step 4 gained medical fluid, 0.1% active carbon is added, stand 30min, adsorb endotoxin, pass sequentially through 0.22um Miillpore filter twice, removes active carbon；

Step 6；Step 5 gained medical fluid is taken, packing in Pyrex control bottle, is partly jumped a queue into 20mL, for injection to be lyophilized； Step 7: taking injection to be lyophilized obtained by step 5, freeze-drying, Quan Jiasai obtains finished product.

Claims (9)

1. a kind of compound multicomponent injection, which is characterized in that by danshensu, Paeoniflorin, ligustrazine, hydroxyl radical carthamin yellow carthamus A It is formed with pharmaceutically acceptable auxiliary material.

2. compound multicomponent injection as described in claim 1, composition are as follows:

Preparation process:

Step 1: taking 80% water for injection of recipe quantity, sequentially add solubilizer, antioxidant stirs, dissolution；

Step 2: successively take recipe quantity danshensu, ligustrazine, Paeoniflorin, hydroxyl radical carthamin yellow carthamus A sets in step 1 acquired solution, Stirring, dissolution；

Step 3；Recipe quantity stabilizer is taken, is added in step 2 acquired solution, is stirred, dissolution；

Step 4；It adds to the full amount of water for injection, is 5.5- with 0.1M hydrochloric acid or 3 acquired solution pH value of sodium hydroxide regulating step 6.0；

Step 5: taking step 4 gained medical fluid, 0.1% active carbon is added, stand 30min, adsorb endotoxin, pass sequentially through 0.22um Miillpore filter twice, removes active carbon；

Step 6；Step 5 gained medical fluid is taken, into 20mL in borosilicate glass ampoule, sealing is injection subject to sterilization for packing；

Step 7: taking injection subject to sterilization obtained by step 6,121 DEG C, moist heat sterilization 15min is cooled to room temperature, obtains finished product.

3. compound multicomponent injection as claimed in claim 2, it is characterised in that the solubilizer is polyoxyethylene sorbitan monoleate；It is described anti- Oxygen agent is ascorbic acid；The stabilizer is glycerol.

4. compound multicomponent injection as claimed in claim 3, composition are as follows:

5. compound multicomponent injection as claimed in claim 3, composition are as follows:

6. compound multicomponent injection as claimed in claim 3, composition are as follows:

7. any compound multicomponent injection as described in claim 1-6, which is characterized in that preparation step is as follows:

Step 1: taking 80% water for injection of recipe quantity, sequentially add polyoxyethylene sorbitan monoleate, ascorbic acid stirs, dissolution；

Step 2: successively take recipe quantity danshensu, ligustrazine, Paeoniflorin, hydroxyl radical carthamin yellow carthamus A sets in step 1 acquired solution, Stirring, dissolution；

Step 3；Recipe quantity glycerol is taken, is added in step 2 acquired solution, is stirred, dissolution；

Step 4；It adds to the full amount of water for injection, is 5.5- with 0.1M hydrochloric acid or 3 acquired solution pH value of sodium hydroxide regulating step 6.0；

Step 5: taking step 4 gained medical fluid, 0.1% active carbon is added, stand 30min, adsorb endotoxin, pass sequentially through 0.22um Miillpore filter twice, removes active carbon；

Step 6；Step 5 gained medical fluid is taken, into 20mL in borosilicate glass ampoule, sealing is injection subject to sterilization for packing；

Step 7: taking injection subject to sterilization obtained by step 6,121 DEG C, moist heat sterilization 15min is cooled to room temperature, obtains finished product.

8. the compound multicomponent injection as described in claim 1-6, it is characterised in that administration mode is drug administration by injection.

9. the compound multicomponent injection as described in claim 1-6 is used to prepare the purposes for the treatment of medication for treating pyemia.